Consensus Prelude Therapeutics Incorporated

Equities

PRLD

US74065P1012

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
4.07 ^USD	+0.74%		+9.41%	-4.68%

10/04	Bryant D. Lim to Serve as Principal Financial Officer and Principal Accounting Officer of Prelude Therapeutics Incorporated	CI
10/04	Prelude Therapeutics Incorporated Announces Chief Financial Officer Changes	CI

Evolution of the average Target Price on Prelude Therapeutics Incorporated

Price target over the last 5 years

History of analyst recommendation changes

957c561e68b94e77ac3d390.NlXq4uZtjDZqKKUEdUECCl5FnrSFme6glsv7Dy1hiRc.fTOIgZIey3hTY9dTQjhpU2xzyoftzqjT_J_CQxRQ4k8BBbyqpCfPezht8A~d21057224dc797b0902ffae79675d8bc

Analyst Recommendations on Prelude Therapeutics Incorporated

JMP Securities Starts Prelude Therapeutics With Market Outperform Rating, $7 Price Target	13/03	MT
HC Wainwright Downgrades Prelude Therapeutics to Neutral From Buy, Price Target is $5	20/02	MT
Morgan Stanley Downgrades Prelude Therapeutics to Underweight From Equalweight, Cuts Price Target to $4 From $10	19/12	MT
HC Wainwright Trims Prelude Therapeutics' Price Target to $5 From $6, Keeps Buy Rating	08/11	MT
HC Wainwright Adjusts Price Target on Prelude Therapeutics to $6 From $17, Keeps Buy Rating	19/23/19	MT
Barclays Adjusts Price Target on Prelude Therapeutics to $5 From $7, Maintains Equalweight Rating	04/23/04	MT
HC Wainwright Adjusts Price Target on Prelude Therapeutics to $17 From $15, Maintains Buy Rating	17/23/17	MT
HC Wainwright Adjusts Prelude Therapeutics' Price Target to $15 From $16, Keeps Buy Rating	17/22/17	MT
Morgan Stanley Trims Price Target on Prelude Therapeutics to $10 From $11, Maintains Equalweight Rating	15/22/15	MT
Morgan Stanley Downgrades Prelude Therapeutics to Equalweight From Overweight, Cuts Price Target to $11 From $19	09/22/09	MT
Jefferies Initiates Prelude Therapeutics at Buy With $9 Price Target	29/22/29	MT
HC Wainwright Adjusts Prelude Therapeutics Price Target to $16 From $62, Maintains Buy Rating	12/22/12	MT
Morgan Stanley Adjusts Prelude Therapeutics Price Target to $19 From $20, Maintains Overweight Rating	17/22/17	MT
BofA Securities Downgrades Prelude Therapeutics to Neutral From Buy, Adjusts Price Target to $10 From $50	15/22/15	MT
Barclays Downgrades Prelude Therapeutics to Equalweight From Overweight, Adjusts Price Target to $12 From $20	28/22/28	MT
Barclays Adjusts Prelude Therapeutics' Price Target to $20 From $33, Reiterates Overweight Rating	17/21/17	MT
PRELUDE THERAPEUTICS INCORPORATED : Morgan Stanley Upgrades Prelude Therapeutics to Overweight Rating From Equal-Weight, Adjusts Price Target to $35 From $60	11/21/11	MT
PRELUDE THERAPEUTICS INCORPORATED : Barclays Adjusts Prelude Therapeutics' Price Target to $33 from $80, Keeps Overweight Rating	08/21/08	MT
PRELUDE THERAPEUTICS INCORPORATED : BofA Securities Upgrades Prelude Therapeutics to Buy From Neutral; Price Target is $60	27/21/27	MT
PRELUDE THERAPEUTICS INCORPORATED : HC Wainwright Starts Prelude Therapeutics at Buy With $62 Price Target	26/21/26	MT
PRELUDE THERAPEUTICS INCORPORATED : Morgan Stanley Adjusts Prelude Therapeutics PT to $60 From $47, Maintains Equal Weight Rating	17/21/17	MT
PRELUDE THERAPEUTICS INCORPORATED : Barclays Starts Prelude Therapeutics at Overweight With $80 Price Target	09/21/09	MT
PRELUDE THERAPEUTICS INCORPORATED : BofA Securities Downgrades Prelude Therapeutics to Neutral From Buy	20/20/20	MT
PRELUDE THERAPEUTICS INCORPORATED : Morgan Stanley Adjusts Prelude Therapeutics' Price Target to $38 From $34, Keeps at Equal Weight	12/20/12	MT